wire - news in brief



Results 1 - 50 of 1523.
1 2 3 4 5 ... 31 Next »

Pharmacology - Health - 14.01.2021
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th

Pharmacology - Health - 12.01.2021
Second COVID-19 vaccine approved for Switzerland
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.

Health - Pharmacology - 05.01.2021
New Ebolavirus treatment sees the light thanks to basic research performed in Ticino
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.

Pharmacology - Health - 19.12.2020
Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.

Life Sciences - Pharmacology - 18.12.2020
A weather station for epileptic seizure
A weather station for epileptic seizure
The unpredictability of epileptic seizures is a severe handicap for patients.

Pharmacology - Health - 16.12.2020
Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients' quality of life 1-3 C3 glomerulopathy (C3G) is a

Pharmacology - Health - 16.12.2020
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval co

Health - Pharmacology - 15.12.2020
New synthetic molecule can kill the flu virus
New synthetic molecule can kill the flu virus
Scientists have developed a synthetic molecule capable of killing the virus that causes influenza. They hope their discovery will lead to an effective drug treatment.

Pharmacology - Health - 15.12.2020
Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In

Health - Pharmacology - 11.12.2020
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number

Health - Pharmacology - 09.12.2020
Novartis Kisqali demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri

Health - Pharmacology - 09.12.2020
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri

Research Management - Pharmacology - 09.12.2020

Pharmacology - Health - 08.12.2020
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif * in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito

Pharmacology - Health - 08.12.2020
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an

Pharmacology - Health - 05.12.2020
Novartis analyses confirm benefit of Kymriah with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L

Pharmacology - Health - 04.12.2020
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic

Health - Pharmacology - 02.12.2020
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif

Health - Pharmacology - 30.11.2020
Taco mattresses take the pressure off hospitals
Taco mattresses take the pressure off hospitals
During the lockdown last spring, Julian Ferchow put his doctoral project aside to help relieve the strain on hospitals.

Health - Pharmacology - 25.11.2020
Infusion more effective than tablets: Treatment of iron anaemia in rural Africa
Infusion more effective than tablets: Treatment of iron anaemia in rural Africa
Iron-deficiency anaemia is a major concern in low income countries, especially for women. A study conducted in Tanzania has now demonstrated the advantage of iron infusion therapy over the usual treatment with iron tablets.

Health - Pharmacology - 25.11.2020
Tackling pandemic threats proactively
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.

Health - Pharmacology - 18.11.2020
Coronavirus: simplified, faster generation of SwissCovid app codes
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.

Pharmacology - Health - 13.11.2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p

Pharmacology - Health - 13.11.2020
Results from real-world data and post-hoc analysis of Novartis Beovu pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi

Health - Pharmacology - 06.11.2020
Novartis provides update on CAN-COVID trial in hospitalized patients
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilatio

Pharmacology - Health - 05.11.2020
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx at Week 12 vs.

Health - Pharmacology - 30.10.2020
Contact tracing with prophylactic treatment could near-eliminate leprosy
Contact tracing with prophylactic treatment could near-eliminate leprosy
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programmes, and is generally well accepted by patients, their contacts, and healthcare workers.

Pharmacology - Health - 29.10.2020
Novartis presents latest Phase III data reinforcing Cosentyx as a first-line systemic treatment in pediatric psoriasis
Latest data show Cosentyx provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile 1,2 Moderate-to-severe psoriasis affects more than 350,0

Health - Pharmacology - 29.10.2020
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Acquisition expands the Novartis footprint in ophthalmology and enhances the company's position as an AAV-based gene therapy powerhouse.
1 2 3 4 5 ... 31 Next »